Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer in a Nigerian Cohort pCR post chemotherapy for breast cancer

Olalekan Olasehinde (1), Oluwatosin Omoyiola (2), Adewale Aderounmu (3), Olaejirinde Olaofe (4), Tolulope Komolafe (5), Oludolapo Omoyiola (6), Shariff Folorunso (7), Adewale Adisa (8), Olusegun Alatise (9), Oladejo Lawal (10)
(1) Department of Surgery, Obafemi Awolowo University Ile-Ife, Nigeria; Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(2) Department of Morbid Anatomy and Forensic Medicine, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(3) Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(4) Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(5) Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(6) Oncology unit, Obafemi Awolowo University Teaching Hospitals Comple, Ile-Ife, Nigeria, Nigeria,
(7) Oncology unit, Obafemi Awolowo University Teaching Hospitals Comple, Ile-Ife, Nigeria, Nigeria,
(8) Department of Surgery, Obafemi Awolowo University Ile-Ife, Nigeria; Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(9) Department of Surgery, Obafemi Awolowo University Ile-Ife, Nigeria; Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria,
(10) Department of Surgery, Obafemi Awolowo University Ile-Ife, Nigeria; Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex Ile-Ife, Nigeria, Nigeria

Abstract

Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) is a marker for important clinical outcomes in the management of breast cancer. In Nigeria where the majority of patients are candidates for NAC, there is limited data on pCR following NAC. This study evaluated the pCR rate in a cohort of Nigerian patients.


Methods: A retrospective review of patients who had NAC and mastectomy for breast cancer between 2017 and 2022. Relevant baseline clinicopathological and treatment data were obtained, pCR was defined as the absence of invasive cancer with or without in situ disease in the breast. The relationship between receptor status, type of chemotherapy and pCR was evaluated.


Results: One hundred and sixty six of the 250 patients who had mastectomy during the period had NAC and were eligible for analysis. The mean age was 50.1±11.1, the majority had stage 3 disease. Overall (pCR) rate was 19.9% with the latter part of the study corresponding to the period with increased use of taxanes, having higher pCR (35.9% in 2022 vs 7.4% in 2017, p=0.024). Patients with HER 2 positive/Hormone receptor negative (HER 2+/HR-), HER 2+/HR+ and triple negative disease had  significantly higher pCR than those with HR+/HER 2 negative disease (38.9%, 30.8%, 24.5% and 6.5%  respectively, p=0.03). 


Conclusion: NAC resulted in pCR in about one-fifth of the entire cohort, particularly those with potentially aggressive HER 2+ and triple negative disease. The use of taxanes was associated with higher pCR rates.

Full text article

Generated from XML file

References

Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. JNCI: Journal of the National Cancer Institute. 2005 Feb 2 [cited 2023 Aug 20];97(3):188–94. doi: 10.1093/jnci/dji021.

Hayes DF, Schott AF. Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator? JNCI Monographs [Internet]. 2015 May 1 [cited 2023 Aug 20];2015(51):36–9. doi: 10.1093/jncimonographs/lgv004.

Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. 2016 Sep 21;15(7):2483–93. doi: 101200/JCO19971572483.

Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, et al. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. J Am Coll Surg. 2015 Jun 1;220(6):1063–9.

Heil J, Pfob A, Morrow M. De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment. Lancet Oncol. 2021: 1;22(4):435–6. Available from: http://www.thelancet.com/article/S1470204521000577/fulltext

Colomer R, Saura C, Sánchez‐Rovira P, Pascual T, Rubio IT, Burgués O, et al. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist. 2019:1;24(5):603. Available from: /pmc/articles/PMC6516119/

Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Ann Surg Oncol. 2021 Apr 1;28(4):2111–9. Available from: https://link.springer.com/article/10.1245/s10434-020-09480-9

Loibl S, Denkert C, von Minckwitz G. Neoadjuvant treatment of breast cancer – Clinical and research perspective. The Breast. 2015 Nov 1;24:S73–7.

Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research [Internet]. 2020 Jun 15 [cited 2023 Aug 20];26(12):2838–48. Available from: https://dx.doi.org/10.1158/1078-0432.CCR-19-3492

Romanoff A, Olasehinde O, Goldman DA, Alatise OI, Constable J, Monu N, et al. Opportunities for Improvement in the Administration of Neoadjuvant Chemotherapy for T4 Breast Cancer: A Comparison of the U.S. and Nigeria. Oncologist [Internet]. 2021 Sep 1 [cited 2023 Aug 20];26(9):e1589–98. Available from: https://dx.doi.org/10.1002/onco.13814

Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology. 2003 Nov 15;21(22):4165–74.

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. https://doi.org/101200/JCO19981682672. 2016 Sep 21;16(8):2672–85.

Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. The American Journal of Surgery. 2009 Oct 1;198(4):520–5.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal of the National Comprehensive Cancer Network [Internet]. 2017 Oct 1 [cited 2023 Aug 20];15(10):1216–23. Available from: https://jnccn.org/view/journals/jnccn/15/10/article-p1216.xml

Değerli E, Şentürk Öztaş N, Alkan G, Bedir Ş, Derin S, Valıkhanova N, et al. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. https://doi.org/101080/1120009X20222043514 [Internet]. 2022 [cited 2023 Aug 20];35(1):29–38. Available from: https://www.tandfonline.com/doi/abs/10.1080/1120009X.2022.2043514

Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, et al. Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy. J Breast Cancer [Internet]. 2012 Jun 28 [cited 2023 Aug 20];15(2):203–10. Available from: https://synapse.koreamed.org/articles/1036338

Kim S Il, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. Oncology [Internet]. 2011 Apr 1 [cited 2023 Aug 20];79(5–6):324–30. Available from: https://dx.doi.org/10.1159/000322192

Okoye J. High prevalence of triple-negative breast cancer and poor survival outcome in Nigeria: A call for further molecular subtyping of triple-negative breast cancer. Annals of Tropical Pathology [Internet]. 2020 Jan 1 [cited 2023 Aug 20];11(1):98–98. Available from: https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22510060&v=2.1&it=r&id=GALE%7CA632211531&sid=googleScholar&linkaccess=fulltext

Menkiti FE, Ukah CO, Menkiti IO, Onyiaorah IV, God’swill Chigbo C, History A. the changing immunohistochemical profile of breast carcinomas in Nnewi, South-East Nigeria: our experience: Medico Research Chronicles [Internet]. 2021 Dec 5 [cited 2023 Aug 20];8(6):518–28. Available from: http://medrech.com/index.php/medrech/article/view/541

Google Scholar [Internet]. [cited 2023 Aug 20]. Available from: https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=https%3A%2F%2Fwww.clintonhealthaccess.org%2Fnews%2Fnigeria-launches-public-private-partnership-to-ensure-affordable-access-to-high-quality-chemotherapies-at-seven-teaching-hospitals%2F&btnG=

Boughey JC, McCall LM, Ballman K V., Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg [Internet]. 2014 [cited 2023 Aug 20];260(4):608. Available from: /pmc/articles/PMC4159769/

Ntekim A, Nufu FT, Campbell OB. Breast cancer in young women in Ibadan, Nigeria. Afr Health Sci [Internet]. 2009 [cited 2023 Aug 20];9(4):242–6. Available from: https://www.ajol.info/index.php/ahs/article/view/52147

Olasehinde O, Arije O, Wuraola FO, Samson M, Olajide O, Alabi T, et al. Life without a breast: Exploring the experiences of young Nigerian women after mastectomy for breast cancer. J Glob Oncol. 2019 May 16;2019(5):1–6.

Authors

Olalekan Olasehinde
lekanolasehinde@yahoo.com (Primary Contact)
Oluwatosin Omoyiola
Adewale Aderounmu
Olaejirinde Olaofe
Tolulope Komolafe
Oludolapo Omoyiola
Shariff Folorunso
Adewale Adisa
Olusegun Alatise
Oladejo Lawal
1.
Olasehinde O, Omoyiola O, Aderounmu A, Olaofe O, Komolafe T, Omoyiola O, Folorunso S, Adisa A, Alatise O, Lawal O. Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer in a Nigerian Cohort : pCR post chemotherapy for breast cancer . Arch Breast Cancer [Internet]. 2023 Sep. 1 [cited 2024 May 23];10(4):354-60. Available from: https://www.archbreastcancer.com/index.php/abc/article/view/769

Article Details